6-K

SUMMIT THERAPEUTICS PLC

Date: April 14, 2020

/s/ Robert Duggan

Robert Duggan

Chief Executive Officer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2020.

Commission File Number 001-36866

SUMMIT THERAPEUTICS PLC

(Translation of registrant’s name into English)

136a Eastern Avenue

Milton Park, Abingdon

Oxfordshire OX14 4SB

United Kingdom

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On April 14, 2020, Summit Therapeutics plc (the “Company”) announced that Mr. Robert Duggan had been appointed as Chief Executive Officer (“CEO”) of the Company. In addition to serving as CEO, Mr. Duggan will continue in his role as Chairman of the Board of Directors (the “Board”) of the Company. Mr. Duggan has agreed to serve as CEO without compensation. The Company also announced that Mr. Glyn Edwards resigned as CEO of the Company, effective as of April 14, 2020. Mr. Edwards will continue to serve as a member of the Board. The related press release is attached hereto as Exhibit 99.1.

This Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-232074).

EXHIBIT INDEX


Exhibit Number		Description

99.1		Press Release, dated April 14, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.